Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

References

Page 1

	Year	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, New England Journal of Medicine	2020	15.1K
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine New England Journal of Medicine	2020	10.4K
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Jerald Sadoff, Glenda Gray, An Vandebosch, New England Journal of Medicine	2021	2.5K
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Wilfredo F. García-Beltrán, Evan C. Lam, Kerri St. Denis, Cell VaccinationMultiple Sars-cov-2 VariantsVaccine DevelopmentImmunologyHumoral Immunity	2021	1.5K
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant Shabir A. Madhi, Vicky L. Baillie, Clare Cutland, New England Journal of Medicine	2021	1.3K
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine New England Journal of Medicine	2021	1.1K
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine UCL Discovery (University College London)	2021	662
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, New England Journal of Medicine	2021	652
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley, The Lancet	2021	649

Page 1